OnKure Therapeutics (OKUR) Net Equity Issued and Repurchased (2020 - 2023)

OnKure Therapeutics (OKUR) has 4 years of Net Equity Issued and Repurchased data on file, last reported at -$5.1 million in Q4 2023.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$5.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $53.8 million (changed N/A YoY) and the FY2023 annual result came in at $53.8 million, up 27766.84% from the prior year.
• Net Equity Issued and Repurchased retreated to -$5.1 million in Q4 2023, from $57.9 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $57.9 million in Q2 2023 to a low of -$5.1 million in Q4 2023.
• A 4-year average of $24.5 million and a median of $24.0 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased sank 100.0% — and 2023, when it soared 16716.67%.
• Tracing OKUR's Net Equity Issued and Repurchased over 4 years: stood at $47.4 million in 2020, then slumped by 100.0% to -$1000.0 in 2021, then jumped by 700.0% to $6000.0 in 2022, then sank by 84750.0% to -$5.1 million in 2023.
• The last three Net Equity Issued and Repurchased figures came in at -$5.1 million (Q4 2023), $57.9 million (Q2 2023), and $1.0 million (Q1 2023), per Business Quant data.